Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKKMarkus Borner, Walter Mingrone, Thomas Ruhstaller et al.|Annals of Oncology|2008Cited by 129
Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07Daniel Helbling, Dieter Koeberle, G. Bodoky et al.|Annals of Oncology|2012Cited by 86
Outcomes of watch and wait after short-course radiotherapy in an international multicentre watch-and-wait cohortBarbara M. Geubels, Peirong Ding, Aart-Jan van den Esschert et al.|British journal of surgery|2024Cited by 8
Neoadjuvant chemoradiation (CRT) with or without panitumumab (Pan) in patients with K-ras-unmutated, locally advanced rectal cancer (LARC): A randomized multicenter phase II trial (SAKK 41/07).Daniel Helbling, Dieter Koeberle, G. Bodoky et al.|Journal of Clinical Oncology|2011Cited by 4
Neoadjuvant chemoradiation (CRT) with or without panitumumab (Pan) in patients with K-ras unmutated, locally advanced rectal cancer (LARC): Final results of a randomized multicenter phase II trial (SAKK 41/07).Daniel Helbling, Dieter Koeberle, G. Bodoky et al.|Journal of Clinical Oncology|2015Cited by 0